Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject;

• wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD;
• and
• wherein the agonist is a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:
• wherein:
• R1 is sec-butyl, C6-10 aryl, —CH2—(C6-10)aryl, —CH2-heterocycle, C4-8 cycloalkyl, C3-8 cycloalkenyl or heterocycle;
• R2 is halogen or methyl;
• R3 is halogen;
• R4 is H, methyl or halogen;
• R5 is OR6 or NH2;
• and
• R6 is H or C2-4 alkyl;
• or wherein the agonist is a compound selected from the group consisting of:
• and pharmaceutically acceptable salts thereof.